Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repinotan safety and PK in healthy elderly
NCT02223507Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2000
- Primary completion
- Sep 2000
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial of repinotan in ischemic stroke (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of subjects with adverse events at 8 days, Number of subjects with clinically significant findings in vital functions at 8 days and 2 more. Started Aug 2000; status: completed.
02
Drugs
repinotan
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02223507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223507.